Keryx Biopharmaceuticals Inc. (KERX: Quote) announced Monday morning that its Phase 3 study of Zerenex, for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis, met the study’s primary endpoint.Keryx Biopharmaceuticals gapped up sharply Monday and climbed throughout the middle portion of the trading day. Shares finished with a gain of 2.63 at $6.06 on the highest volume of the year. The stock broke out to a new high for the year.
Click here to receive FREE breaking news email alerts for Keryx Biopharmaceuticals Inc and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.comBusiness News